Previous studies have shown that colorectal cancer patients with G13D mutations benefit from first-line chemotherapy plus cetuximab, but their progression-free survival (PFS), OS, and response rates(RR) are still lower than those of patients with wild-type KRAS tumors (37). The gene discussed is KRAS; the disease is colorectal cancer.